London, England – April 23, 2026 – Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, released two-year outcomes data today from the company’s first-in-human (FIH) trial of their investigational Nectero EAST® System. The results were presented at Charing Cross 2026 by Dr. Andrew Holden during a session on Abdominal Aortic Aneurysm (AAA) disease management.Continue reading→

AIRNA, a clinical-stage company developing RNA-editing medicines with an initial focus on AATD, joins C-Path’s antitrypsin consortium upon initiation of its RepAIR1 global clinical study.Continue reading→

On April 14, NIH’s Seed Fund (Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs) was reauthorized for the next five years. The reauthorization restores momentum, improves the programs, and reopens pathways for both new applicants and currently funded projects.Continue reading→

[Seattle, WA] April 15, 2026 – Apprenti, the leading national intermediary for Registered Apprenticeship (RA), is proud to announce the formal approval and filing of the National Biomanufacturing Technician Standards with the U.S. Department of Labor (USDOL). Crafted under the strategic guidance of the Apprenti Life Science Advisory Board—which includes leaders from Pfizer, Merck, Thermo Fisher, and Biogen—these standards were developed in close partnership with the Life Sciences Workforce Collaborative (LSWC) and InnovATEBIO as part of a high-impact NIIMBL project. Continue reading→

Seven Arizona-based research teams have been awarded $100,000 grants from the Flinn Foundation as members of the 2026 Translational Seed Grants Program cohort. The new awardees represent six institutions — two from Arizona State University and one each from HonorHealth Research Institute, Mayo Clinic Arizona, Northern Arizona University, Translational Genomics Research Institute, or TGen, and University of Arizona. Barrow Neurological Institute, Black Canyon Bio, Smile Train, University of California, Davis, NAU, UCLA and Ohio State University all serve as partners on the projects, which address conditions including Valley fever, epilepsy, cleft conditions, and brain cancer.Continue reading→

The AZAdvances Health Innovation Showcase featured an exciting lineup of Arizona-based innovators revolutionizing the future of healthcare through technologies, data solutions, and patient-focused strategies. During the event, numerous companies across diagnostics, digital health, therapeutics, and care delivery presented their ideas and visions for the future.Continue reading→

GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, and researchers from the University of California, Irvine (UCI) today announced the publication of a joint study in the Proceedings of the National Academy of Sciences (PNAS). The peer-reviewed paper validates a novel drug candidate, GATC-1021, which was identified using GATC Health’s Operon™ AI platform to more precisely target the specific neurological dysregulations found in individuals with Opioid Use Disorder (OUD).Continue reading→